Jul 12, 2024

FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC

➞

Jun 05, 2024

Multi-Indication Efficacy of Mabwell's 9MW2821 Highlighted in Oral Presentation at 2024 ASCO

➞

May 24, 2024

Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting

➞

May 16, 2024

Mabwell Presented Pre-clinical Data of 2MW3311 at PEGS 2024

➞

May 14, 2024

FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

➞

May 12, 2024

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

➞

May 08, 2024

Mabwell's MW032 Included in CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer

➞

May 06, 2024

FDA Grants Orphan Drug Designation to 9MW2821

➞

Apr 26, 2024

Mabwell to Debut Clinical Study Results of 9MW3011 at EHA2024

➞

Apr 25, 2024

Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor at ASCO 2024

➞